S5-E11.4 – More Hot MASLD Topics: Inflammation, MD Columnists’ Advice, FGF-21s
This conversation includes the rest of the panelists’ hot topics plus Michael Charlton’s dive into FGF-21s.
April 19, 2024
This conversation includes the rest of the panelists’ hot topics plus Michael Charlton’s dive into FGF-21s.
Michael Charlton, Jörn Schattenberg and Louise Campbell each identify a specific paper or event they consider exciting and important.
Michael Charlton and the Surfers discuss two issues: defining therapeutic futility for Rezdiffra and describing some advances in MASLD translational medicine
Michael Charlton describes the impact of Rezdiffra on practices and procedures in his clinic
Michael Charlton joins the Surfers for a far-reaching conversation, with topics ranging from how his clinic is integrating Rezdiffra in MASH patient treatment to exciting research, both reported and in development.
Hepatologist Tim Jobson, co-founder of Predictive Health Intelligence, joins Louise Campbell and Roger Green to provide an update on PHI’s work and discuss implications for databases, patient recruitment and special population issues.
Hannes Hagstrom joins the Surfers to explore the ways that increased access to and awareness of VCTE or other in-office scanning will improve MASLD therapy.
Hannes Hagstrom join the Surfers in discussing studies that demonstrate the value of different nutritional approaches in driving improved liver health.
MASLD patient advocates consider new needs and opportunities for other stakeholders after the Rezdiffra approval and launch.
MASLD patient advocates consider the impact Rezdiffra approval and accompanying promotion and education might have on the U.S. healthcare system.